N-[(2,4-二氯苯基)甲基]-4-[(甲基磺酰基)氨基]苯甲酰胺 | 825658-06-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-[(2,4-二氯苯基)甲基]-4-[(甲基磺酰基)氨基]苯甲酰胺
• 英文名称: N-[(2,4-Dichlorophenyl)methyl]-4-[(Methylsulfonyl)amino]benzamide
• 英文别名: N-[(2,4-dichlorophenyl)methyl]-4-(methanesulfonamido)benzamide
• CAS: 825658-06-8
• 化学式: C₁₅H₁₄Cl₂N₂O₃S
• 分子量: 373.3
• InChiKey: RDFIQTZRJRVFHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Activator of TREK (TWIK RElated K+ channels) channels
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US11046683B2

  公开（公告）日：2021-06-29

  Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.

  本发明公开了一种式 (I) 的化合物： 其中所有符号在描述中定义。还公开了包含所述化合物的药物组合物、制造所述化合物的方法、包含所述化合物的试剂盒，以及使用所述化合物、组合物和试剂盒治疗哺乳动物中与 TREK-1、TREK-2 或 TREK-1 和 TREK-2 功能障碍相关的疾病的方法。
• ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20190322662A1

  公开（公告）日：2019-10-24

  Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.
• [EN] ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS<br/>[FR] ACTIVATEUR DE CANAUX TREK (CANAUX K+ ASSOCIÉS À TWIK)
  申请人：ONO PHARMACEUTICAL CO

  公开号：WO2018110669A1

  公开（公告）日：2018-06-21

  Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.